Welcome to our dedicated page for Cerus SEC filings (Ticker: CERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Cerus Corporation’s progress—from FDA interactions on its INTERCEPT Blood System to global supply contracts—means digging through dense SEC disclosures that often exceed 200 pages. Form 8-K updates on clinical milestones, convertible-note financings, and intricate R&D footnotes can be hard to locate, while Form 4 insider trading data moves quickly. If you have ever asked, “How do I read a Cerus annual report 10-K simplified?” or searched for “Cerus insider trading Form 4 transactions,” you know the challenge.
Stock Titan solves this complexity. Our AI-powered summaries translate each Cerus quarterly earnings report 10-Q filing into plain language, flagging segment revenue from platelet and plasma kits, cash-burn trends, and regulatory commentary. Real-time alerts surface “Cerus Form 4 insider transactions real-time,” so you can monitor executive stock transactions before they influence sentiment. Need context on a sudden secondary offering? Our platform links the related 8-K material events explained and provides side-by-side financial ratios, letting you focus on decisions, not document hunting.
Beyond numbers, investors use this page to uncover details unique to a blood-safety company: projected INTERCEPT adoption rates hidden in the MD&A, royalty obligations buried in footnotes, and board-level proposals inside the proxy statement executive compensation. Whether you’re comparing R&D outlays quarter over quarter, assessing dilution risk, or simply seeking “understanding Cerus SEC documents with AI,” every filing type—from the annual report 10-K to the proxy—arrives here first, complete, searchable, and explained. Cerus earnings report filing analysis has never been clearer.
Cerus Corporation (CERS) filed a Form 8-K to announce a governance change effective June 16, 2025. Long-standing board chair Daniel N. Swisher, Jr. retired from the board and its committees with no reported disagreements over company matters. To maintain continuity, the board moved quickly on June 20 to promote CEO William M. Greenman to chair while appointing Frank Witney, Ph.D. as lead independent director. Both directors will serve in their existing board classes, expiring at the 2026 and 2027 annual meetings, respectively. No other operational or financial data were disclosed in the filing.
The change consolidates the CEO and chair roles, offset by the creation of a lead independent director position intended to preserve board oversight. Investors should view the update as a routine succession matter with limited immediate financial impact but modest corporate-governance implications.
FAQ
What is the current stock price of Cerus (CERS)?
What is the market cap of Cerus (CERS)?
What is the core business of Cerus Corporation?
How does the INTERCEPT Blood System work?
In which regions does Cerus market its products?
What distinguishes Cerus from other biomedical companies?
What types of blood products are treated with the INTERCEPT System?
How does the technology address emerging pathogen threats?
What is the main revenue source for Cerus Corporation?
How does Cerus ensure compliance with regulatory standards?
